
Arta Monir Monjazeb MD PhD
Professor and Director of Radiobiology, Radiation Oncology, UC Davis Health
Join to View Full Profile
4501 X Street, G120Uc Davis Health System Department Of Radiation OncologySacramento, CA 95817
Phone+1 336-575-2977
Dr. Monjazeb is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a Professor of Radiation Oncology and a clinician scientist leading the clinical care of patients, a high-powered basic science research enterprise, and innovative human clinical trials. I have extensive experience leading teams of diverse individuals from varying disciplines in activities including clinical trials, basic science research, clinical care, education, and diversity / inclusion. I serve(d) in leadership roles on an institutional and national level including: PI of an R01 funded basic science research laboratory; heading GI and sarcoma radiotherapy at UC Davis; Director of the Cancer Immunology and Energetics Program at UC Davis Comprehensive Cancer Center; Director of Radiobiology for the UC Davis Department of Radiation Oncology; NRG Oncology Immunotherapy Committee Co-Chair; NIH TIR study section; and PI of institutional investigator initiated trials and national clinical trials.
My clinical expertise is in the treatment of gastrointestinal malignancies and sarcomas. I hold national leadership positions and have published extensively on the management of these diseases.
My research has two major themes. The first focuses on understanding and exploiting the mechanisms of radiation induced immune modulation. The second is understanding how aging and obesity affects inflammation and immunity in the context of cancer development, progression, and therapy with a particular focus on radiotherapy. My research is translational in nature spanning from basic mechanistic studies to murine models to large animal companion canine clinical trials and human clinical trials. I am uniquely trained for this line of research with an honors thesis in immunology at the University of California, Berkeley, a PhD in Cancer Biology and Inflammation, a Holman pathway research fellowship in cancer immunology, board certification as a radiation oncologist, and training through the UC Davis K12 program in translational cancer immunotherapy.
Education & Training
Wake Forest University Baptist Medical CenterResidency, Radiation Oncology, 2006 - 2010
Los Angeles County-Harbor-UCLA Medical CenterInternship, Transitional Year, 2005 - 2006
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2005
University of California, BerkeleyBA, Molecular and Cellular Biology, with Honors, 1993 - 1997
Certifications & Licensure
CA State Medical License 2010 - 2027
NC State Medical License 2006 - 2010
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
- UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Start of enrollment: 2018 Jan 17
- UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Start of enrollment: 2019 May 20
Publications & Presentations
PubMed
- 3 citationsUpdates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.Fereshteh Talebi, Fabiana Gregucci, Jalal Ahmed, Nir Ben Chetrit, Brian D Brown
Oncoimmunology. 2025-12-01 - A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.Jonathan W Riess, Matthew S Lara, Guillaume Luxardi, Miguel Lopez de Rodas, Michiko Shimoda
JTO Clinical and Research Reports. 2025-06-01 - 8 citationsProceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.Zachary S Morris, Sandra Demaria, Arta M Monjazeb, Silvia C Formenti, Ralph R Weichselbaum
The Lancet. Oncology. 2025-03-01
Journal Articles
- PD-1 Blockade Reverses Obesity-Mediated T Cell Priming ImpairmentArta Monjazeb, MD, Frontiers in Immunology
- Paradoxical Effects of Obesity on T Cell Function During Tumor Progression and PD-1 Checkpoint BlockadeR Rivkah Isseroff, Emanual Maverakis, Robert J Canter, Kurt A Schalper, Karen Kelly, Bruce R Blazar, Catherine T Le, Dan L Longo, Arta M Monjazeb, Sami Ibrahimi, Nature
- The Challenge for Development of Valuable Immuno-Oncology BiomarkersArta M Monjazeb, Janice M Mehnert, Lyndsay N Harris, Clinical Cancer Research
Press Mentions
How Does Obesity Affect Immunity, Cancer and Radiotherapy? It’s Complicated!January 26th, 2023
Colon and Rectal Cancer on the Rise in Young AdultsMarch 9th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









